The FDA or Food and Drug Administration is a federal agency within the United States. The FDA is responsible for regulating the manufacturing, marketing, and distribution of tobacco products tin the US.
After reviewing the scientific evidence on IQOS, the US FDA has authorized the marketing  of IQOS, concluding that:
•The IQOS system heats tobacco but does not burn it.
•The absence of combustion significantly reduces the production of harmful or potentially harmful chemicals.
•Scientific studies have shown that switching completely from cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.*
 
Important information: IQOS is not risk-free. It delivers nicotine, which is addictive.

* Source: FDA’s marketing order for the IQOS system dated July 7, 2020.

MRTP stands for Modified Risk Tobacco Product.
 
On July 7, 2020, the US Food and Drug Administration (FDA) authorized IQOS to be marketed in the US with a claim of reduced exposure to harmful chemicals. This makes IQOS the first and only heated tobacco system  authorized as a  Modified Risk Tobacco Product with reduced exposure information  in the US*.
 
The US FDA decision came after several years of reviews of all of the scientific evidence available on IQOS. Between the opening and the closure of the scientific review, the FDA asked 86 questions related to the applications, seeking clarifications or additional data.
 
After reviewing the scientific evidence on IQOS, the US FDA has authorized the marketing of IQOS, concluding that:
The IQOS system heats tobacco but does not burn it.
The absence of combustion significantly reduces the production of harmful or potentially harmful chemicals.
Scientific studies have shown that switching completely from cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.*
 
Important information: IQOS is not risk-free. It delivers nicotine, which is addictive.
 
* Source: FDA’s marketing order for the IQOS system dated July 7, 2020.

 The US FDA decision of authorizing IQOS to be marketed with a reduced exposure information shows that IQOS is a fundamentally different product compared to cigarettes and a better choice for adults who would otherwise continue smoking. Unlike cigarettes, the IQOS system heats tobacco instead of burning it. This significantly reduces the production of harmful and potentially harmful chemicals compared to cigarette smoke.
Furthermore, scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces the body’s exposure to harmful or potentially harmful chemicals.*


Important information: IQOS is not risk-free. It delivers nicotine, which is addictive.

* Source: PMI 3-month reduced exposure studies conducted in Japan and the US in near real world conditions. These studies measured exposure to 15 harmful chemicals, and compared to the levels observed in smokers who switched to IQOS with levels measured in smokers who continued to smoke cigarettes.

Similar to our IQOS heat-not-burn system, vaping products are smoke-free alternatives to continued smoking. However, there are also important differences between the two. E-cigarettes don’t contain tobacco. Instead, they heat an e-liquid containing nicotine and flavors to produce an aerosol.
So far, no vaping product has been authorized for marketing under MRTP application process by the US FDA.
The IQOS system is the first and only tobacco heating system authorized in the US as a  Modified Risk Tobacco Product. The FDA concluded that switching completely from cigarettes to IQOS reduces the body’s exposure to harmful or potentially harmful chemicals.*

Important information: IQOS is not risk-free. It delivers nicotine, which is addictive.

* Source: PMI 3-month reduced exposure studies conducted in Japan and the US in near real world conditions. These studies measured exposure to 15 harmful chemicals, and compared to the levels observed in smokers who switched to IQOS with levels measured in smokers who continued to smoke cigarettes.

The US FDA’s decision of authorizing IQOS to be marketed in US with reduced exposure information  encourages us to continue our mission of replacing cigarettes with science-based, smoke-free products applying our responsible marketing practices.
PMI’s marketing practices must always adhere to the following four core principles:
1) We only market and sell our products to adult smokers.
2) We warn consumers about the health effects of our products.
3) Our marketing is honest, transparent and accurate.
4) We respect the law.

The FDA, or the Food and Drug Administration, is the government agency in the United States responsible for protecting the public health. The FDA regulates a variety of consumer products, including tobacco. However, the US law expressly prohibits making any claims that a tobacco product is “FDA approved,” as their evaluation standards are not appropriate for such products. Instead, the FDA authorizes or not the marketing of tobacco products as “modified risk tobacco products” in US.
 

Philip Morris submitted a set of MRTP applications for the IQOS system. After thorough reviews, the FDA issued a modified exposure order recognizing that switching completely from cigarettes to our smoke-free alternative, IQOS, reduces the exposure to harmful or potentially harmful chemicals*.

Important information: IQOS is not risk-free. It delivers nicotine, which is addictive.

* Source: PMI 3-month reduced exposure studies conducted in Japan and the US in near real world conditions. These studies measured exposure to 15 harmful chemicals, and compared to the levels observed in smokers who switched to IQOS with levels measured in smokers who continued to smoke cigarettes.